Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.69 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19839760 | 1.00 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC1 | |
| SCHEMBL6216449 | 0.86 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7241098 | 0.86 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22919394 | 0.83 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13589901 | 0.82 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5497908 | 0.82 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26288696 | 0.82 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5375565 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5034067 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5374487 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151809-A1 | INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | CHRNB2 33/4885CHRNA4 51/4885CHRNB4 97/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CHRNB2 33/4885CHRNA4 51/4885CHRNB4 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.